Will the mRNA vaccine platform be the panacea for the development of vaccines against antimicrobial resistant (AMR) pathogens?

Expert Rev Vaccines. 2022 Feb;21(2):155-157. doi: 10.1080/14760584.2022.2011226. Epub 2021 Dec 3.

Author

Wangxue Chen^{1

2}

Affiliations

¹ Human Health Therapeutics Research Center (HHT), National Research Council Canada, Ottawa, Ontario, Canada.
² Department of Biology, Brock University, St. Catharines, Ontario, Canada.

PMID: 34818960
DOI: 10.1080/14760584.2022.2011226

No abstract available

Keywords: Antimicrobial Resistance (AMR); alternatives to antibiotics; bacterial infection; mRNA vaccine; vaccine.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Anti-Infective Agents*
Drug Resistance, Bacterial
Humans
Vaccines, Synthetic* / genetics
mRNA Vaccines

Substances

Anti-Infective Agents
Vaccines, Synthetic
mRNA Vaccines